WHO issues warning for growing resistance to HIV drug of GSK

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-03-11 12:28 GMT | Update On 2024-06-20 19:05 GMT

The World Health Organization (WHO) has said resistance to GSK's HIV drug dolutegravir has exceeded levels observed during its trials, citing observational and survey data received from a few countries.

Resistance ranged from 3.9% to 8.6% and reached 19.6% among people who have received and transitioned to a dolutegravir-containing antiretroviral therapy (ART) regimen to combat high HIV viral loads.

For more information click on the link below:

WHO Warns Of Growing Resistance To GSK HIV Drug

Full View

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Roshni Dhar

Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

WHO issues warning for growing resistance to HIV drug of GSK

Similar News